Implementation of diagnostic 131I whole-body scans within 24 hours after the second recombinant human thyrotropin (rhTSH) injection is feasible and reliable in differentiated thyroid cancer (DTC) patients.
High concordance rates (over 90%) between early diagnostic scans at 18 and 24 hours versus post-therapy scans support immediate pre-treatment disease evaluation.
Serum thyroglobulin (sTg) measurements at 24 hours post-rhTSH correlate strongly with 72-hour levels, reflecting consistent biochemical disease status.
This accelerated protocol enables radioiodine therapy (RAIT) within the same two-injection rhTSH cycle, potentially reducing costs and improving clinical workflow.
